Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation
Clinical trial NCT06106308 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06106308
- Sponsor
- Cardiff Oncology
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-02-27
- Primary completion
- 2026-11-01
- Enrollment
- 110
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.